Effects of growth hormone on intestinal adaptation of rat with short bowel syndrome

Influence of rhGH on postoperative immune function of patients with obstructive jaundice

AIM: To observe the clinical significance and changes of cytoimmunity, humoral immunity and immune regulatory factors after the administration of rhGH on patients with obstructive jaundice (OJ).

METHODS: A prospective, randomized and controlled clinical study was performed, and 36 OJ cases were randomly divided into control group (A group, n = 18) and rhGH group (B group, n = 18). rhGH were added in group B. A dynamic investigation of cytoimmunity indices (CD3⁺, CD4⁺ and CD4⁺/CD8⁺), humoral immunity indices (IgA, IgG and IgM) and serum immune regulatory factors (IL-2, IL-6 and TNF-α) were conducted and mortality rate and complication rate of patients of two groups before therapy and at 1, 8 d after operation were evaluated.

RESULTS: Indexes of cytoimmunity indices (CD3⁺, CD4⁺ and CD4⁺/CD8⁺) in B group were obviously improved than A (42.32% ± 4.19% vs 31.51% ± 4.42%; 26.36% ± 4.25% vs 19.29% ± 4.27%; 1.22 ± 0.20 vs 0.95 ± 0.12, all P < 0.05). Humoral immunity indices (IgA, IgG and IgM) in B group were obviously improved than group A 8 days after treatment (2.42 ± 0.11 g/L vs 1.41 ± 013 g/L; 6.88 ± 0.18 g/L vs 4.89 ± 0.15 g/L; 1.84 ± 0.18 g/L vs 1.28 ± 0.24 g/L, all P < 0.05). Erum immune regulatory factors (IL-6 and TNF-α) were significantly decreased in B group (0.42 ± 0.11 mg/L vs 0.86 ± 0.10 mg/L; 11.04 ± 1.52 pmol/L vs 18.24 ± 1.22 pmol/L, both P < 0.05), IL-2 was obviously improved in group B (1.92 ± 0.15 mg/L vs 1.14 ± 0.12 mg/L, P < 0.05), and mortality rate and complication rate in group B were obviously lower than group A (22.22% vs 44.44%, 0.00% vs 5.56%, both P < 0.05).

CONCLUSION: RhGH has a direct immunoregulatory effect on patients with obstructive jaudice, which improves immunity of patients with obstructive jaundice and is good for their recovery.